Cargando…

Anti-tumor effects of rigosertib in high-risk neuroblastoma

High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma. Among several hundred cancer cell lines representing 24 tumor typ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radke, Katarzyna, Hansson, Karin, Sjölund, Jonas, Wolska, Magdalena, Karlsson, Jenny, Esfandyari, Javanshir, Pietras, Kristian, Aaltonen, Kristina, Gisselsson, David, Bexell, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207190/ https://www.ncbi.nlm.nih.gov/pubmed/34118691 http://dx.doi.org/10.1016/j.tranon.2021.101149

Ejemplares similares

Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance
por: Mañas, Adriana, et al.
Publicado: (2022)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2019)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2020)

Patient-derived models: Advanced tools for precision medicine in neuroblastoma
por: Aaltonen, Kristina, et al.
Publicado: (2023)

Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
por: Valind, Anders, et al.
Publicado: (2023)

Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019)

The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis
por: Holmquist Mengelbier, Linda, et al.
Publicado: (2018)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

Upregulated functional gene expression programmes in tumour pericytes mark progression in patients with low‐grade glioma
por: Oudenaarden, Clara, et al.
Publicado: (2021)

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
por: Jansson, Sara, et al.
Publicado: (2018)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2021)

Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
por: Valind, Anders, et al.
Publicado: (2021)

Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum
por: Persson, Camilla U., et al.
Publicado: (2017)

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2014)

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020)

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Regarding human cytomegalovirus in neuroblastoma
por: Forslund, Ola, et al.
Publicado: (2014)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Discovery of epi-Enprioline as a Novel Drug for the Treatment of Vincristine Resistant Neuroblastoma
por: Sime, Wondossen, et al.
Publicado: (2020)

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2017)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours
por: Braekeveldt, Noémie, et al.
Publicado: (2015)

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
por: Dietrich, Peter, et al.
Publicado: (2017)

Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling
por: Eleftheriou, Nikolas M., et al.
Publicado: (2016)

Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas
por: Gisselsson, David, et al.
Publicado: (2007)

Novel Nano-Sized MR Contrast Agent Mediates Strong Tumor Contrast Enhancement in an Oncogene-Driven Breast Cancer Model
por: Eriksson, Per-Olof, et al.
Publicado: (2014)

Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer
por: Bocci, Matteo, et al.
Publicado: (2018)

The immune cell atlas of human neuroblastoma
por: Verhoeven, Bronte Manouk, et al.
Publicado: (2022)

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
por: Hyoda, Tomoko, et al.
Publicado: (2015)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Engineered human mesenchymal stem cells for neuroblastoma therapeutics
por: Nieddu, Valentina, et al.
Publicado: (2019)

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines
por: Prasad, Anil, et al.
Publicado: (2016)

Label-free separation of neuroblastoma patient-derived xenograft (PDX) cells from hematopoietic progenitor cell products by acoustophoresis
por: Olm, Franziska, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5qav47lqc94hfp6tsas8giuann